xcube.bio

xcube.bio (Xcubebio AG) is a Swiss-based market entry accelerator and platform company designed to help late-stage biopharma innovators navigate the commercialization and market entry of transformative therapeutics in Europe and international markets. Founded in 2024, the company utilizes a unique 'NewCo' co-investment model, combining equity, hands-on advisory, and deep-tech automation to de-risk and streamline the transition from clinical development to commercial launch. Rather than licensing assets out entirely, innovators partner with xcube.bio to build their own commercial footprint and retain long-term ownership. The company's team of over 40 industry experts supports product profiling, regulatory processes, Health Technology Assessments (HTA), and launch execution.